Efficacy of Four Solanum spp. Extracts in an Animal Model of Cutaneous Leishmaniasis

• Main Authors: Paul Cos, Jo Janssens, Abel Piñón, Osmany Cuesta-Rubio, Arianna Yglesias-Rivera, Alexis Díaz-García, Wagner Vilegas, Lianet Monzote
• Format: Article
• Language: English
• Published: MDPI AG 2018-06-01
• Series: Medicines
• Subjects: Leishmania amazonensis; cutaneous leishmaniasis; BALB/c mice; Solanum havanense; Solanum myriacanthum; Solanum nudum; Solanum seaforthianum
• Online Access: http://www.mdpi.com/2305-6320/5/2/49

Background: Leishmaniasis is a complex protozoa disease caused by Leishmania genus (Trypanosomatidae family). Currently, there have been renewed interests worldwide in plants as pharmaceutical agents. In this study, the in vivo efficacy of Solanum spp. is assessed in an L. amazonensis BALB/c mice model for experimental cutaneous leishmaniasis. Methods: Animals were infected with 5 × 106 metacyclic promastigotes and 30-day post-infection, a treatment with 30 mg/kg of Solanum extracts or Glucantime® (GTM) was applied intralesionally every four days to complete 5 doses. Results: Neither death nor loss of weight higher than 10% was observed. All the tested extracts were able to control the infection, compared with the infected and untreated group. Solanum havanense Jacq. extract showed the highest efficacy and was superior (p < 0.05) to GTM. Solanum myriacanthum Dunal., S. nudum Dunal. and S. seaforthianum Andr. extracts demonstrated a similar effect (p > 0.05) to GTM. An increase of IFN-γ (p < 0.05) was displayed only by animals treated with S. nudum compared to the group treated with a vehicle, while no differences (p > 0.05) were observed for IL-12. Conclusions: In vivo effects of Solanum extracts were demonstrated, suggesting that this genus could be further explored as a new antileishmanial alternative.